Patients and caregivers
Prepare for your visit.
Prepare for your visit, learn how to read a bottle’s page, and take the discussion guide with you.
Every bottle has a page.
Micelle 60 is a hemp-derived CBD isolate softgel in development, with a planned label amount of 60 mg per softgel. Each released lot is intended to have a public Quality Passport containing its certificate, measured values, notices and corrections.
Illustrative packaging visual based on Label draft v1, 29 September 2026.
Two clear paths
Continue with the path that fits you.
Care organizations
Review the product together.
Review the product, quality evidence, organization workflow and patient materials.
Start here
Three facts before anything else.
What it is
A hemp-derived CBD isolate softgel in development, with a planned label amount of 60 mg per softgel. Each bottle is planned to contain 60 softgels.
Read the product recordHow it is intended to be supplied
Only through participating care organizations, within a physician-guided shared decision-making process. It is not offered for retail sale.
See the patient pathwayWhat will be public
Every released lot will have a public Quality Passport containing its release status, certificate, measured values, notices, and corrections.
See the Quality PassportQuality Passport
One page for every bottle.
Use a Quality Passport to check a bottle’s contents, current lot status, certificate, and any notice. Bottles from the same lot share one record. The examples below use sample data; released-lot pages open with the first shipment.
No released commercial lot exists yet. The records below are examples with sample data.
See how the Quality Passport worksSelected lot record
Example A · Micelle 60
CBD per softgel59.7 mgExample
Total THC per containerNot detectedExample · broader federal finished-product restriction begins December 11, 2026
Certificate statusCurrent exampleExample
These are demonstration values for a finished-product lot record, not ingredient-certificate values. Read the sourced federal timing and product-compliance boundary.
Report ID: Sample report A-001
Example document; sample data; UI demonstration
Micelle 60 Example A certificate
- Version
- 2026-09-29
- Date
- 29 September 2026
- Pages
- 2
- File size
- 55 KB
- Status
- Released example record; not a laboratory report or manufactured or released product
Detailed laboratory results6 example results
| Analyte | Specification | Result | Method | Status |
|---|---|---|---|---|
| CBD per softgelExample | 60 mg planned label amount | 59.7 mg | HPLC | Pass |
| Total THC per containerExample | ≤ 0.4 mg from Dec 11, 2026 | Not detected | HPLC | Pass |
| Heavy metalsExample | Within release specification | Pass | ICP-MS | Pass |
| PesticidesExample | Not detected above limits | Pass | LC-MS/MS | Pass |
| Residual solventsExample | Within release specification | Pass | HS-GC-MS | Pass |
| MicrobialsExample | Within release specification | Pass | USP methods | Pass |
Formulation story
Why it is called Micelle.
The sequence below explains the design idea behind the formulation and the product name.
01 / 05
01
One softgel.
The planned label amount is 60 mg of CBD in a lipid-based formulation.
02
Inside the softgel.
CBD sits in a clear, lipid-based liquid inside the shell.
03
Meeting fluid.
The formulation is designed to disperse into smaller structures on contact with fluid.
04
Micelles form.
The illustration shows small structures around a CBD-containing center. Their size and shape can vary.
05
Then the lot is measured.
The lot record is where measured CBD, total THC per container, test methods, and status are published. The formulation is still in development.
Example measured dataConceptual illustration only. Size, arrangement, and particle form are illustrative, not measured; this does not show what happens in a person.
Company
Company and next steps.
NW Micelle Therapeutics, Inc. is a Delaware company and part of the NW PharmaTech group.
Micelle 60 is a distinct product with its own formulation, specification, and evidence.